Finance

Biotech Active Runners: Galena Biopharma Inc. (NASDAQ:GALE), Gilead Sciences (NASDAQ:GILD), Rexahn Pharmaceuticals (NYSEMKT:RNN), Inovio Pharmaceuticals Inc. (NYSEMKT:INO)

Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of holders of Galena Biopharma, Inc. (NASDAQ:GALE) securities between November 6, 2013 and February 14, 2014. Galena Biopharma Inc. (NASDAQ:GALE) stock performance was -12.42% in last session and finished the day at $2.82. Traded volume was 17.65 million shares in the last session and the average volume of the stock remained 9.21 million shares. The beta of the stock remained 0.82. Galena Biopharma Inc. (NASDAQ:GALE) insider ownership is 0.60%.

Gilead Sciences (NASDAQ:GILD) Director John Francis Cogan sold 14,000 shares of the company’s stock on the open market in a transaction dated Friday, March 14th. The stock was sold at an average price of $76.44, for a total value of $1,070,160.00. Following the completion of the sale, the director now directly owns 39,542 shares in the company, valued at approximately $3,022,590.
Gilead Sciences, Inc. (NASDAQ:GILD) rose 3.07% to $77.77 yesterday on volume of 10.33 million shares. The intra-day range of the stock was $75.51 – $78.06. Gilead Sciences, Inc. (NASDAQ:GILD) has a market capitalization of 119.29 billion.

Yesterday Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) may have found its muse in its RX-5902, now named Supinoxin finally. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)’s stock on March 18, 2014 reported a higher of 4.69% to the closing price of $1.34. Its fifty two weeks range is $0.28 – $1.85. The total market capitalization recorded 174.82 million. The overall volume in the last trading session was 8.66 million shares. In its share capital, Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) has 130.47 million outstanding shares.

Inovio Pharmaceuticals Inc. (NYSEMKT:INO) on Mar. 17 reported financial results for the fourth quarter and year ended Dec. 31, 2013. On Tuesday, shares of Inovio Pharmaceuticals Inc. (NYSEMKT:INO) advanced 0.29% to close the day at $3.43. Company return on investment (ROI) is -68.30% and its monthly performance is recorded as 24.73%. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) quarterly revenue growth is 73.23%.